NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
Rain Oncology Inc
University of Washington
Washington University School of Medicine
Hoffmann-La Roche
Health Pharma Professional Research
Hoffmann-La Roche
Queen Mary University of London
Yale University